vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $207.8M, roughly 1.2× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 34.5%, a 22.9% gap on every dollar of revenue.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
IDYA vs WSBC — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $257.2M |
| Net Profit | $119.2M | $88.6M |
| Gross Margin | — | — |
| Operating Margin | 52.2% | — |
| Net Margin | 57.4% | 34.5% |
| Revenue YoY | — | — |
| Net Profit YoY | 330.1% | 54.4% |
| EPS (diluted) | $1.33 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | — | $265.6M | ||
| Q3 25 | $207.8M | $261.6M | ||
| Q2 25 | — | $260.7M | ||
| Q1 25 | — | $193.2M | ||
| Q4 24 | — | $162.9M | ||
| Q3 24 | $0 | $150.8M | ||
| Q2 24 | $0 | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | — | $91.1M | ||
| Q3 25 | $119.2M | $83.6M | ||
| Q2 25 | — | $57.4M | ||
| Q1 25 | — | $-9.0M | ||
| Q4 24 | — | $49.6M | ||
| Q3 24 | $-51.8M | $37.3M | ||
| Q2 24 | $-52.8M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 43.2% | ||
| Q3 25 | 52.2% | 39.5% | ||
| Q2 25 | — | 27.2% | ||
| Q1 25 | — | -5.0% | ||
| Q4 24 | — | 38.0% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | — | 34.3% | ||
| Q3 25 | 57.4% | 31.9% | ||
| Q2 25 | — | 22.0% | ||
| Q1 25 | — | -4.7% | ||
| Q4 24 | — | 30.5% | ||
| Q3 24 | — | 24.7% | ||
| Q2 24 | — | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | — | $0.97 | ||
| Q3 25 | $1.33 | $0.84 | ||
| Q2 25 | — | $0.57 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | — | $0.72 | ||
| Q3 24 | $-0.60 | $0.54 | ||
| Q2 24 | $-0.68 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $4.1B |
| Total Assets | $1.2B | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $956.1M | ||
| Q3 25 | $786.9M | $1.0B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $568.1M | ||
| Q3 24 | $920.0M | $620.9M | ||
| Q2 24 | $701.7M | $486.8M |
| Q1 26 | — | $4.1B | ||
| Q4 25 | — | $4.0B | ||
| Q3 25 | $1.1B | $4.1B | ||
| Q2 25 | — | $3.8B | ||
| Q1 25 | — | $3.8B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | $1.2B | $2.8B | ||
| Q2 24 | $931.7M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | — | $27.7B | ||
| Q3 25 | $1.2B | $27.5B | ||
| Q2 25 | — | $27.6B | ||
| Q1 25 | — | $27.4B | ||
| Q4 24 | — | $18.7B | ||
| Q3 24 | $1.2B | $18.5B | ||
| Q2 24 | $973.7M | $18.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | — |
| Free Cash FlowOCF − Capex | $142.2M | — |
| FCF MarginFCF / Revenue | 68.4% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $290.4M | ||
| Q3 25 | $142.2M | $116.9M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $-26.4M | ||
| Q4 24 | — | $211.0M | ||
| Q3 24 | $-49.2M | $60.7M | ||
| Q2 24 | $-32.9M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $280.0M | ||
| Q3 25 | $142.2M | $114.9M | ||
| Q2 25 | — | $98.3M | ||
| Q1 25 | — | $-30.7M | ||
| Q4 24 | — | $200.7M | ||
| Q3 24 | $-49.7M | $56.9M | ||
| Q2 24 | $-33.9M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 105.4% | ||
| Q3 25 | 68.4% | 43.9% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | — | 123.2% | ||
| Q3 24 | — | 37.7% | ||
| Q2 24 | — | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.9% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | — | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | 1.19× | 1.40× | ||
| Q2 25 | — | 1.83× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDYA
Segment breakdown not available.
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
